Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Workshop of the Carolinas 2024 | Asciminib for the treatment of CML

Gabriela Hobbs • 25 Aug 2024
MPN Workshop of the Carolinas 2024
Chronic Myeloid Leukemia Leukemia Asciminib

In this video, Gaby Hobbs, MD, Massachusetts General Hospital, Boston, MA, briefly discusses the approval of asciminib for the treatment of relapsed/refractory (R/R) chronic myeloid leukemia (CML), a key advancement in the treatment landscape for this hematological malignancy. The agent is also being tested in the frontline setting. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy- Abbvie, BMS, GSK, Novartis, Pfizer, Pharmaessentia, Incyte.

More from Gabriela Hobbs

Cardiovascular risk factors and pulmonary hypertension in patients with MPNs 1:30
Cardiovascular risk factors and pulmonary hypertension in patients with MPNs
Gabriela Hobbs • 25 Aug 2024
Key considerations for physicians when faced with a pregnant patient with MPN 1:06
Key considerations for physicians when faced with a pregnant patient with MPN
Gabriela Hobbs • 25 Aug 2024
Clinical approaches to fertility and pregnancy in patients with MPNs 1:04
Clinical approaches to fertility and pregnancy in patients with MPNs
Gabriela Hobbs • 25 Aug 2024
Future directions in chronic phase CML treatment 1:20
Future directions in chronic phase CML treatment
Gabriela Hobbs • 11 Dec 2021

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals